Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 42 clinical trials
International Phase 3 Trial in Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph+ALL) Testing Imatinib in Combination With Two Different Cytotoxic Chemotherapy Backbones

This randomized phase III trial studies how well imatinib mesylate works in combination with two different chemotherapy regimens in treating patients with newly diagnosed Philadelphia chromosome positive acute lymphoblastic leukemia (ALL). Imatinib mesylate has been shown to improve outcomes in children and adolescents with Philadelphia chromosome positive (Ph+) ALL when …

leucovorin
conjugated bilirubin
combination chemotherapy
lymphoid leukemia
daunorubicin
  • 310 views
  • 12 Oct, 2022
  • 168 locations
Diminish Chemotherapy Related Side Effects Through Patient Education (D-CRSE)

Currently, there is a lack of patient education materials regarding cytotoxic chemotherapy side effects, research supported treatments, and the utilization of CAM by cancer patients at Penn State Cancer Institute. The investigators aim to develop an educational brochure, which educates patients about the chemotherapy side effects they may experience, and …

  • 0 views
  • 25 Mar, 2022
  • 1 location
Cryotherapy vs. Cryocompression for Preventing Chemotherapy-induced-peripheral-neuropathy in Women Undergoing Chemotherapy

This study's aim is to show a benefit of Cryocompression (cooling hands with additional compression of the hands) in comparison to Cryotherapy (just cooling hands) in female cancer patients (with gynecological cancer) receiving chemotherapy with taxanes. Patients who are not eligible for either cryocompression or cryotherapy are included in a …

  • 0 views
  • 26 Jan, 2021
  • 1 location
A Phase 1/2 Study of [225Ac]-FPI-1434 Injection

This is a first-in-human Phase 1/2, non-randomized, multi-centre, open-label clinical trial designed to investigate safety, tolerability, pharmacokinetics (PK) and preliminary anti-tumour activity of [111In]-FPI-1547 Injection (radioimmuno-imaging agent) and [225Ac]-FPI-1434 Injection (radioimmuno-therapeutic) and to establish the maximum tolerated dose (MTD) and/or the recommended Phase 2 dose (RP2D) of repeat doses of …

  • 51 views
  • 07 Oct, 2022
  • 19 locations
Safety and Efficacy Study of Tislelizumab in Combination With BCG in HR-NMIBC Patients (TACBIN-01)

This study is a single-arm, open-label, single-center study to assess the safety of tislelizumab with BCG, and to obtain the preliminary efficacy results in subjects who have been diagnosed with high-risk NMIBC without prior BCG treatment.

metastasis
neutrophil count
carcinoma in situ
intravesical chemotherapy
carcinoma
  • 0 views
  • 20 Jun, 2021
  • 1 location
TACE Sorafenib and PD-1 Monoclonal Antibody in the Treatment of HCC

Hepatocellular carcinoma (HCC) is the fourth most common cause of cancer-related death that ranks sixth in terms of incident cases, with an overall 5 years survival of 18%. Despite a significant improvement in treatment strategy, the overall survival of HCC remains low due to high recurrence, progressive liver dysfunction and …

measurable disease
hepatocellular carcinoma
monoclonal antibody
carcinoma
cancer
  • 0 views
  • 26 Jan, 2021
  • 1 location
A Phase 1b Dose Escalation and Dose Expansion Study Evaluating the Safety, Pharmacokinetics, and Antitumor Activity of Furmonertinib in Patients With Advanced or Metastatic Non-Small Cell Lung Cancer With Activating EGFR or HER2 Mutations, Including Exon 20 Insertion Mutations

This is a Phase 1b, open-label, multi-center, dose-escalation and dose-expansion study designed to evaluate the safety, pharmacokinetics (PK), and preliminary antitumor activity of furmonertinib in patients with advanced or metastatic NSCLC with activating EGFR or HER2 mutations, including Exon 20 insertion mutations. Patients will be enrolled into 2 stages: Stage …

primary cancer
EGFR
lung carcinoma
experimental drug
osimertinib
  • 0 views
  • 28 Oct, 2022
  • 4 locations
Possible Protective Effect of Celecoxib Against Capecitabine Induced Hand and Foot Syndrome in Patients With Colorectal Cancer (HFS)

chemotherapeutic agent. The mechanisms of HFS are still unknown, and there are limited data available on how to prevent them or manage them. However, different hypotheses of capecitabine-induced HFS pathogenesis

  • 0 views
  • 05 May, 2022
  • 1 location
Study of BLU-451 in Advanced Cancers With EGFR Exon 20 Insertion Mutations

This is a Phase 1/2, open-label study of the safety, pharmacokinetics (PK), pharmacodynamics, and anti-tumor activity of single-agent BLU-451. All patients will receive BLU-451 as a single agent administered once daily (QD) or twice daily (BID) on a 21-day treatment cycle.

primary cancer
measurable disease
systemic therapy
liquid biopsy
corticosteroids
  • 0 views
  • 04 Oct, 2022
  • 4 locations
(HARMONY) Study of BLU-701 in EGFR-mutant NSCLC

This is a Phase 1/2, open-label, first-in-human (FIH) study is designed to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and antitumor activity of BLU-701 as monotherapy or in combination with either osimertinib or platinum-based chemotherapy in patients with EGFRm NSCLC.

EGFR
carboplatin
osimertinib
platinum-based chemotherapy
cancer chemotherapy
  • 0 views
  • 10 Jul, 2022
  • 7 locations